- Home
- CHI vs PHAR Comparison
CHI vs PHAR Comparison
Compare CHI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- PHAR
- Stock Information
- Founded
- CHI 2002
- PHAR 1988
- Country
- CHI United States
- PHAR Netherlands
- Employees
- CHI N/A
- PHAR N/A
- Industry
- CHI Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- PHAR Health Care
- Exchange
- CHI Nasdaq
- PHAR Nasdaq
- Market Cap
- CHI 853.5M
- PHAR 951.7M
- IPO Year
- CHI N/A
- PHAR N/A
- Fundamental
- Price
- CHI $11.29
- PHAR $13.14
- Analyst Decision
- CHI
- PHAR Strong Buy
- Analyst Count
- CHI 0
- PHAR 3
- Target Price
- CHI N/A
- PHAR $30.00
- AVG Volume (30 Days)
- CHI 186.2K
- PHAR 11.1K
- Earning Date
- CHI 01-01-0001
- PHAR 11-06-2025
- Dividend Yield
- CHI 9.90%
- PHAR N/A
- EPS Growth
- CHI N/A
- PHAR N/A
- EPS
- CHI N/A
- PHAR N/A
- Revenue
- CHI N/A
- PHAR $339,836,000.00
- Revenue This Year
- CHI N/A
- PHAR $17.70
- Revenue Next Year
- CHI N/A
- PHAR $12.25
- P/E Ratio
- CHI N/A
- PHAR N/A
- Revenue Growth
- CHI N/A
- PHAR 22.44
- 52 Week Low
- CHI $9.70
- PHAR $7.31
- 52 Week High
- CHI $11.61
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- CHI 60.47
- PHAR 43.07
- Support Level
- CHI $10.86
- PHAR $13.08
- Resistance Level
- CHI $11.50
- PHAR $14.10
- Average True Range (ATR)
- CHI 0.16
- PHAR 0.53
- MACD
- CHI 0.01
- PHAR -0.15
- Stochastic Oscillator
- CHI 69.12
- PHAR 6.18
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.